As­traZeneca wins ku­dos for pipeline turn­around in a new rank­ing of the top 10 R&D play­ers in the bio­phar­ma world

Two years ago, af­ter the first leg of As­traZeneca’s high­ly tout­ed MYS­TIC study failed, with Imfinzi and treme­li­mum­ab flunk­ing a ma­jor test in lung can­cer, the phar­ma gi­ant’s R&D group looked like they were about to be put on life sup­port. To­day, they’re be­ing hailed as the most in­no­v­a­tive and in­ven­tive ma­jor play­er in drug de­vel­op­ment to­day.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER